IRVINE, CA -- (Marketwire) -- 04/11/11 -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that Paul S. Nassif, M.D., FACS and Founder of Spalding Drive Cosmetic Surgery and Dermatology, has been named to the Company's Scientific Advisory Board.
"I welcome the opportunity to join AtheroNova's Scientific Advisory Board," said. Dr. Paul S. Nassif. "The company's core technologies present novel opportunities to address unmet health needs in plastic and reconstructive surgery, and I look forward to working with AtheroNova to explore a range of new treatments to reduce unwanted fatty deposits, lipomas and obesity."
"Dr. Nassif is a noted expert and opinion leader in facial plastic & reconstructive surgery," stated Thomas W. Gardner, CEO of AtheroNova. "We welcome Dr. Nassif's knowledge, guidance and insight as we research, develop and ultimately commercialize a broad range of cosmetic, transdermal and obesity applications for our core delipidization technology."
Dr. Nassif is a board-certified Facial Plastic and Reconstructive Surgeon with a special emphasis on performing Ethnic and Revision Rhinoplasty in Beverly Hills, California. He is a Diplomate of the American Board of Facial Plastic and Reconstructive Surgery, Diplomate of the American Board of Otolaryngology - Head & Neck Surgery and Assistant Clinical Professor of Facial Plastic & Reconstructive Surgery at the University Southern California School of Medicine. Dr. Nassif has appeared on high-profile television series such as Dr. 90210 and The Real Housewives of Beverly Hills.
Dr. Nassif is dedicated to helping patients less fortunate. He participates in "Face to Face," a national organization that offers consults and surgery to victims of domestic violence. Additionally, Dr. Nassif sits on the board of the Sheriff's Youth Foundation, an organization dedicated to building self-esteem in young members of the Los Angeles community.
AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis, obesity and lipomas.
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding the value of Dr. Nassif's appointment to AtheroNova's scientific advisory board, and the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.